Introduction
Molecular alterations that disrupt normal cell death mechanisms and/or augment rates of proliferation can directly contribute to multistep carcinogenesis (McDonnell, 1993) . Additionally, the disruption of cell death signaling pathways is also considered to be an important mechanism by which cancer cells become refractory to various therapeutic agents (McDonnell et al., 1993) . More recent observations suggest that cell death and cell cycle progression must be coordinately regulated (Meikrantz and Schlegel, 1995) . In this regard, the ATP-dependent ubiquitin/proteasome cascade is of particular interest.
The proteasome is a highly conserved, multisubunit complex capable of multiple distinct protease activities (Matthews et al., 1989; Driscoll and Goldberg, 1990; Orlowski, 1990) . The proteasome localizes to the cytoplasm and nucleus of all eukaryotic cells. The 20S proteasome, via an ATP-dependent pathway, associates with other subunits to form a 26S proteasomal complex that can hydrolyze ubiquitinylated proteins (Eytan et al., 1989) . Ubiquitinylation itself is a complexly regulated process. Ubiquitinylation is initiated by a series of ATP-dependent thioester reaction intermediates in which a thioester is formed between the reactive cysteine of E1 (Ubiquitinactivating enzyme), then transferred to a cysteine in E2 (Ubiquitin-conjugating enzyme) and ®nally to a cysteine in E3 (Ubiquitin protein ligase). To date one E1 has been characterized, however, there are at least 10 E2-related enzymes and ®ve E3-related enzymes. The end result of these enzyme activities is the formation of an isopeptide linkage between ubiquitin and the e-amino group of a lysine(s) in the substrate protein, a requisite step for substrate recognition and degradation by the 26S proteasome (for review see Weissman, 1997) .
Proteasomal activity is essential for orderly cell cycle progression in that it mediates the timed degradation of various cell cycle moderators. A condensed list of these moderators includes various cyclins (Sudakin et al., 1995) , the tumor suppressor protein p53 , cdc25 (Nefski and Beach, 1996) , c-mos (Ishida et al., 1993) and the cyclin-dependent kinase inhibitor p27
Kip1 (Pagano et al., 1995) . The proteasome also regulates the timed degradation of important transcription factors including c-jun (Trier et al., 1994) , c-myc (Ciechanover et al., 1991) and STAT1 (Kim and Maniatis, 1996) .
In addition, the proteasome also plays an important role in certain signal transduction pathways activated by stress. For instance, the ATP/ubiquitin-dependent proteasome pathway is the central regulator of the NFkB signaling pathway, in so much as, its activity is indispensable for signal-induced degradation of IkBa, the cytoplasmic inhibitor of NF-kB nuclear import (Palombella et al., 1994) .
We report that use of proteasome inhibitors, at concentrations sucient to block TNF-a-induced IkBa degradation, results in cell death induction in prostate carcinoma cells. Most importantly, the induction of cell death was independent of either ectopic bcl-2 expression or functional p53 expression, two features considered important in prostate cancer progression and therapy failure. Molecular events we observed that were coincident with cell death induction by proteasome inhibition include elevated expression of the putative pro-death signaling eector protein, PAR-4 (Sells et al., 1997; Diaz-Meco et al., 1996) , substantial accumulation of c-jun, a pro-death eector in certain contexts (Bossy-Wetzel et al., 1997) and a modest reduction in bcl-X L protein, an important pro-survival signaling protein related to bcl-2 (Boise et al., 1993) . However, our results do not support a role for the JNK stress kinase pathway in mediating the induction of prostate carcinoma cell death by peptide aldehyde inhibitors of the proteasome.
Our results are consistent with a role for proteasomal activity as a determinant of cell survival in prostate carcinoma cells. The ®ndings further suggest the possibility that manipulation of proteasomal activity might be exploited to therapeutic advantage in advanced-stage prostate cancer despite the common presence of inactivating p53 mutations or high levels of bcl-2 expression.
Results
We recently demonstrated that NF-kB mediates an adaptive survival response in prostate cancer cells stressed with TNF-a (Herrmann et al., 1997a,b) . Further, disruption of NF-kB signaling by using dominant negative inhibitors of IkBa signi®cantly enhanced the cytotoxic eect of TNF-a. The essential role of the ATP/ubiquitin-dependent 26S proteasome Figure 1 Inhibition of signal-induced proteasome-mediated degradation of IkBa by ALLnL and ALLnM. (a) LNCaP cells cultured on laminin-coated coverslips were pretreated with 100 mM E64D, 100 mM ALLnL, 100 mM ALLnM or DMSO (solvent control at the appropriate dilution factor) for 45 min prior to stimulation with recombinant human tumor necrosis factor alpha (TNF-a, 5 ng/ml) for 30 min in the presence or absence of the indicated inhibitor. Cells were immunostained for p65 RelA and imaged for p65 RelA distribution by confocal microscopy. (b) LNCaP cells were treated as described for (a) and extracts immunoblotted for IkBa. The blots were subsequently reprobed for b-actin (loading control). IkBa levels were normalized to b-actin protein levels in the processing and degradation of IkBa, the cytoplasmic inhibitor of NF-kB nuclear import, has also been previously established (Palombella et al., 1994) .
Two peptide aldehydes, acetyl-leucinal-leucinal-norleucinal and acetyl-leucinal-leucinal-normethional (ALLnL or ALLnM), were used to evaluate the impact of selectively inhibiting proteasome function on cell death signaling events. The utility and speci®city of these peptide aldehydes to reversibly inhibit 20S and 26S proteasomal activities, in vitro and in intact cells, has previously been established (Rock et al., 1994) . These peptides were also used recently by Drexler (1997) to study the involvement of the proteasome in cell viability. E64, a cell permeable epoxysuccinyl peptide and irreversible inhibitor of cysteine proteases including calpains, was used as a control treatment.
In order to establish the ability of ALLnL and ALLnM to block the activity of the 26S proteasome in LNCaP cells, we chose to monitor the utility of these peptides to block signal induced IkBa degradation following TNF-a stimulation. Exponentially growing LNCaP carcinoma cells were pretreated with DMSO (solvent control), ALLnL, ALLnM or E64 for 45 min. All inhibitors were used at a ®nal concentration of 100 mM. Cells were then stimulated with 5 ng/ml human recombinant TNF-a in the presence or absence of these inhibitors (100 mM) and whole cell lysates were prepared. Proteasomal inhibition was monitored by assessing IkBa protein levels and the subcellular localization of the NF-kB subunit, p65 RelA, at 30 min post-stimulation with TNF-a (Figure 1a and b) .
ALLnL was modestly more eective than ALLnM at inhibiting TNF-a-induced IkBa degradation, however, both ALLnL and ALLnM eectively blocked p65 RelA nuclear translocation. This result suggests that even a partial block to IkBa degradation in LNCaP cells can signi®cantly impair NF-kB activation. E64 did not demonstrably aect either IkBa degradation or p65 RelA nuclear import (Figure 1a and b) . The potency of ALLnL in blocking signal-induced proteasomemediated degradation of IkBa in RAW macrophages has also been established (Milligan et al., 1996) .
The consequence of the persistent inhibition of proteasome function on modulating cell death susceptibility in prostate carcinoma cells was assessed using spectro¯uorometry and¯uorescence microscopy. Following various treatments LNCaP cells were loaded with CAM, an established¯uorescence indicator of cell viability, and ETHD-1, a DNA binding dye that penetrates only those cells that have compromised plasma membrane integrity. Cells were then analysed spectro¯uorometrically for ETHD-1 and/or calceingenerated¯uorescence. Use of either ALLnL or ALLnM resulted in a signi®cant and dose-dependent decline in cell viability as evidenced by a reduction in calcein-generated¯uorescence (Figure 2) .
Importantly, enforced expression of the pro-survival eector protein bcl-2 in human LNCaP prostate carcinoma cells had no demonstrable eect on the extent of cell death induced by ALLnL. A mean loss of viability of 85% compared to 81% was observed for control and bcl-2 cells, respectively, using 50 mM ALLnL (Figure 2 ). Although less potent at inducing cell death, similar results with respect to a lack of bcl-2-mediated survival advantage were obtained with ALLnM ( Figure 2 ). In this regard, it is important to note that the relative potencies of ALLnL and ALLnM at inducing cell death in LNCaP cells corresponds to their respective potencies at inhibitors of the 26S proteasome measured in terms of relative K i s according to Rock et al. (1994) .
Additionally, we did not observe any diminution of the kinetics of cell death induction in LNCaP-bcl-2 relative to vector control cells over a 24 h period sampled every 2 h (data not shown). Jointly these observations suggest that the mode of cell death initiated by proteasome inhibition in LNCaP prostate carcinoma cells is mediated by a bcl-2-independent pathway.
As a control for general cysteine protease or calpain inhibition, LNCaP and LNCaP-bcl-2 cells were treated with E64 using identical culture conditions. In either vector control or bcl-2 cells, we did not observe any E64-induced cell death, nor any signi®cant changes in cell behavior or morphology even at 100 mM E64 for 24 h (Figure 2) .
In order to ensure ectopically expressed bcl-2 protein was functionally active, parallel experiments were performed using several agents that induce cell death by distinct, albeit unclear, mechanisms. In contrast to the results with ALLnL and ALLnM, expression of bcl-2 conferred signi®cant protection against cell death induction in experiments using C 2 -ceramide and two selective inhibitors of arachidonate metabolism, AA-COCF 3 and ETI (Figure 2) . AACOCF 3 , a tri¯uoro-methylketone analog of arachidonic acid, is a selective inhibitor of cytosolic phospholipase A 2 (cPLA 2 ), the rate-limiting enzyme in the conversion of phospholipid pools to arachidonic acid. ETI is potent inhibitor of and the 5-, 12-and 15-lipoxygenases which convert arachidonic acid to 5-, 12-and 15-hete, respectively Figure 2 Dose-dependent inhibition of human androgensensitive LNCaP prostatic carcinoma cell viability by proteasome inhibitors. Cell viability of calcein AM loaded LNCaP-C or LNCaP-bcl-2 cells at 20 h following proteasome inhibitor treatment or DMSO (control) was determined using a Cyto¯uor uorometric microplate reader. All treatments were performed in triplicate and DMSO was applied at the lowest dilution factor comparable to the dilutions made for 100 mM ALLnL or 100 mM ALLnM treatments. Using identical cell culture conditions, LNCaP or LNCaP-bcl-2 cells were treated with recombinant human TNF-a was used at (5 ng/ml), C 2 -ceramide (10 mM), ETI (10 mM) and AACOCF 3 (10 mM) and terminated at 20 h. Data are presented as relative¯uorescence intensity of calcein and normalized to control cells (DMSO treated) (Bartoli et al., 1994; Reindeau et al., 1994; Street et al., 1993) . A mean cell survival of 83% was observed for LNCaP-bcl-2 compared to 16% for LNCaP-C cells treated with 10 mM C 2 -ceramide. Similarly, for cells treated with AACOCF 3 and ETI we noted that bcl-2 expression conferred a 4.9-and 4.1-fold relative survival advantage, respectively ( Figure 2 ).
Numerous mechanisms might explain the failure of bcl-2 to provide protection against proteasome inhibitors. For example, it has been reported that bcl-2 can be inactivated by phosphorylation induced by certain drugs such as palcitaxel (Haldar et al., 1996; Blagosklonny et al., 1996) . In consideration, we sought to determine whether the ectopically expressed bcl-2 protein might be directly altered by such modi®cation, downregulated or proteolytically processed to an inactive form following proteasome inhibitor treatment. The level of ectopically expressed bcl-2 protein in LNCaP-bcl-2 cells showed no demonstrable alterations following treatment with ALLnL ( Figure 3a) . Also, changes in the apparent molecular weight of bcl-2 protein, indicative of posttranslational modi®cations of bcl-2 such as proteolytic cleavage or phosphorylation, were not observed using 4 ± 20% gradient gels. Such gradient gels, in our hands, have proven quite capable of resolving the M r shift in bcl-2 mobility induced by palcitaxel treatment (not shown).
Modulation of select cell death and survival regulatory proteins were also evaluated following cell death induction by ALLnL in LNCaP and LNCaPbcl-2 cells using immunoblotting techniques. Cell extracts were assessed for expression of the death eector protein, PAR-4, which is upregulated in prostate carcinoma cells undergoing apoptosis (Sells et al., 1997; Diaz-Meco et al., 1996) . Normalized to bactin level, PAR-4 protein is upregulated approximately eightfold within 12 h following ALLnL treatment of LNCaP cells (Figure 3a and b) . Similarly normalized, the extent of PAR-4 induction in LNCaP-bcl-2 cells was approximately threefold by 24 h (Figure 3a and b) .
Interestingly, the level of bcl-X L protein, a prosurvival eector, decreased approximately threefold within 24 h in LNCaP-bcl-2 cells treated with ALLnL but not with DMSO ( Figure 3a and b). In vector control LNCaP cells we observed a comparatively modest decrease in bcl-X L levels was observed within 24 h following ALLnL treatment. The anti-bcl-X antibody used for these studies is cross-reactive with both long and short forms of the bcl-x protein.
Detectable levels of bcl-X s protein were not observed under these experimental conditions.
We next established whether c-jun, a substrate of the 26S proteasome, and an important pro-death eector Figure 3 Regulation of key apoptosis eector proteins during ALLnL-induced cell death of human prostate carcinoma cells. Exponentially growing LNCaP-C and LNCaP-bcl-2 cells were treated with 50 mM ALLnL for the indicated times (hours). Cell extracts were made and gel loading was adjusted to re¯ect equivalent cell numbers. Immunoblots were probed for bcl-2, bcl-X L , Par-4 and b-actin. An image of the amido-black stained membrane is also shown to re¯ect total protein loading. Protein expression was normalized to b-actin levels in certain cellular contexts (Bossy-Wetsel et al., 1997; Trier et al., 1994) might also be post-translationally stabilized in cells treated with ALLnL. We examined whether c-jun was stabilized in exponentially growing human PC-3 prostate carcinoma cells. PC-3 cells treated with 50 mM ALLnL but not DMSO (control) exhibited a substantial elevation in the cellular levels of the c-jun protein (Figure 5a ). In fact, the level of immunoreactive c-jun protein in DMSO control cells remained below the detection limits of the immunoblot analysis, underscoring the substantial stabilization of cjun protein achieved by peptide aldehyde-mediated inhibition of proteasomal activity in PC-3 cells. c-jun protein was also stabilized in ALLnL treated LNCaP cells to a comparable level with similar kinetics (data not shown).
Interestingly, immunoreactive c-jun protein migrated as a triplet under the gel conditions used that is dicult to discern in photographic reproductions of the original autoradiograph, suggestive of the classical serine 63 and serine 73 phosphorylations of c-jun. These phosphorylations are considered activating modi®cations requisite for c-jun-induced apoptosis (Verheij et al., 1996) .
However, using a phospho-JNK mouse monoclonal antibody speci®c for the Thr-183 and Tyr-185 sites of p46 JNK1 and p54 JNK2 that are phosphorylated by SEK1, the upstream activating JNK kinase (Figure 3a) we found that neither JNK1 or JNK2 were phosphorylated in LNCaP cells in response to proteasome inhibitor treatment. As a control for the integrity of the antibody, LNCaP cells were exposed to high Figure 4 Cell death induction in PC-3 prostatic carcinoma cells by the proteasome inhibitor ALLnL. Exponential phase PC-3.neo (vector control), PC-3-bcl-2-23 and PC-3-bcl-2-3 cells were treated with DMSO (solvent control), E64d (100 mM), or ALLnL (25-100 mM) for 24 h. In the third row, detached cells were added back to the appropriate wells of the tissue culture plate to show that all detached cells failed to retain calcein and were heavily loaded with ETHD-1 indicating a loss of plasma membrane integrity. Cells were photographed using epi¯uorescence illumination using a dual band ®lter as described in Materials and methods. Cells retaining calcein appear green. Cells loaded with ETHD-1 have red-orange stained nuclei. The cells exhibit the characteristic morphologic alterations of apoptosis only in the presence of ALLnL intensity ionizing radiation (20 Gy) from a 137 Cs source. Such treatment clearly resulted in a potent, yet transient, phosphorylation of p46 JNK, but not p54 JNK2 by 4 h (data not shown). Equivalent results were obtained with PC-3 cells (data not shown).
Thus, our data using the peptide aldehyde ALLnL indicates that prostate carcinoma cell death induction does not activate the JNK pathway, suggesting a lack of involvement for this key stress pathway in mediating cell death induction by proteasome inhibitors. This result stands in variance to a recent report by Meriin et al., (1998) . Their studies indicate that the catalytic activity of JNK1 can be stimulated in human U937 lymphoid tumor cells and human 293 kidney tumor cells. Moreover, they report that ectopic expression of a catalytically crippled dominant negative JNKK (SEK1) or a transcriptionally inactive mutant version of c-jun lacking the Ser63 and Ser73 sites essential for c-jun activity, blocked cleavage of a co-expressed d12 (a recombinant fragment of U1 ribonucleoprotein) in cells treated with MG132, a potent tripeptide benzyloxycarbonyl proteasome inhibitor. The reasons for the discrepancies between our respective reports can be due to a number of reasons including among others the cell types studied, the proteasome inhibitors chosen and culture conditions. These are discussed in more detail in the discussion section.
The levels of the p116 STAT2 or b-catenin proteins showed no signi®cant alterations following proteasome inhibition by ALLnL in PC-3 cells (Figure 5b and c) . STAT2, unlike STAT1, has not been reported to be a substrate of the 26S proteasome and serves as a loading control. However, the lack of b-catenin stabilization by ALLnL cannot be directly reconciled with the results of Orford et al. (1997) who demonstrated ubiquitinylated b-catenin is a good substrate of the 26S proteasome complex and can be stabilized by treatment of cells with ALLnL.
The possibility that proteasome inhibitors induce cell death in a rather nonspeci®c manner by essentially establishing a global blockade to all protein degradation remains an issue that has not been addressed. In such a scenario, one prediction would be that under conditions whereby proteasomal activity is substantially disrupted, multiple ubiquitinated proteins would accumulate to nonphysiological levels. In order, to monitor the accumulation of ubiquitinated or polyubiquitinated proteins, we used an anti-ubiquitin monoclonal antibody to probe Western blots. Contrary to our expectations, this analysis revealed only a modest accumulation of proteins in the 140 ± 200 kDal size range (Figure 5d ) and another protein migrating at approximately 60 kDal that failed to photograph well.
Of course, the failure to detect multiple ubiquitinated proteins may re¯ect a corresponding increase in isopeptidase activity such that any ubiquitinylated proteins that fail to be recognized by the 26S proteasome complex, could be quickly de-ubiquitinated. This might occur as a sort of negative feedback mechanism. However, we also failed to observe in comparisons of protein expression pro®les, obtained using silver stained polyacrylamide gels, the accumulation of multiple protein species in cells treated with 100 mM ALLnL compared to controls cells that would be suggestive of a generalized block to protein degradation. Nonetheless, although not direct evidence, this observation does intimate that cell death induction by peptide aldehyde inhibitors of proteasomal activity might involve a speci®c signaling program or programs for cell death initiation.
Fluorescence microscopy of CAM and ETHD-1 loaded cells was used to examine cell death of human PC-3 prostate carcinoma cells treated with proteasome inhibitors (Figure 4) . The androgen-insensitive human prostate carcinoma cell line, PC-3, and two bcl-2 expressing congenic PC-3 clones were treated with 100 mM E64d (control), 25 ± 100 mM ALLnL or DMSO (solvent control) as described for the LNCaP cells. At 100 mM ALLnL, most adherent PC-3 cells weakly cleaved calcein AM and retained the calcein product (Figure 4, second row) . Moreover, many adherent PC-3 cells at 100 mM failed to exclude ETHD-1 (Figure 4 , second row). Essentially all detached PC-3 cells at 100 mM failed to retain calcein and were heavily loaded with ETHD-1 (Figure 4, third row) . Equivalent results were obtained at 25 ± 50 mM ALLnL where all detached cells were observed to be dead (data not shown). In summary, the failure of high level ectopic bcl-2 expression in PC-3 cells to provide signi®cant protection against PC-3 cell death resulting from inhibition of proteasomal activity are consistent with the data obtained using the LNCaP and LNCaP-bcl-2 cells.
Finally, we have also evaluated the gross level morphological and ultrastructural alterations in pros- Figure 5 Regulation of key apoptosis eector and proteasome substrate proteins during ALLnL-induced cell death of PC-3 prostate carcinoma cells. PC-3 cells at 80% con¯uency were treated with ALLnL at the indicated concentration or DMSO at an equivalent dilution (control). At the indicated times, cell lysates were prepared and cell equivalents were transferred to nitrocellulose membranes. All blots were consecutively probed using the indicated antibodies and detected by peroxidaseconjugated secondary antibodies using ECL. In (e) a photograph of the proteins remaining the gel post-transfer (coomassie stained) shows the apparent equivalent loading and only a single observable change in total protein levels (unidenti®ed protein migration at 200 kDal). The experiment was repeated with similar observations tate carcinoma cells treated with proteasome inhibitors. Both PC-3 and PC-3-bcl-2 cells treated with ALLnL, but not E64d or DMSO, exhibited morphologic alterations typical of cells undergoing apoptotic cell death. These alterations included cytoplasmic shrinkage (Figure 6 ), nuclear condensation and chromatin fragmentation as assessed by both TEM and confocal imaging of ETHD-1 stained nuclei (Figure 6 ). Several ultrastructural features associated with cell death in LNCaP cells treated with ALLnL were evaluated by transmission electron microscopy (TEM). TEM reveals that the features of cell death induced by ALLnL treatment are nonclassical with respect to the hallmark morphological features of apoptosis. For instance, despite extensive compaction and margination of the chromatin in most ALLnL treated cells (Figure 6b ), the nuclear membrane remains intact and only a few cells appeared to exhibit classical apoptotic body formation (Figure 6c, bottom left) . However, in a few cells the nuclear envelope appeared disjointed (Figure 6c , central), a feature often observed in necrotic cells (Kerr et al., 1972) . On average, in cells treated with ALLnL, the nuclear envelope, if intact, appears rounded relative to control cells in which the nuclear membrane appears convoluted (Figure 6a and b) . Additionally, most of the observed ALLnL-treated cells with the characteristic chromatin pattern have extensive loss of cytosolic granularity, extreme vesiculation and a few mitochondria have lost matrix, three distinct morphological features of necrotic cell death.
Thus, we conclude that cell death induced by ALLnL is atypical, in that many dying cells share features of apoptosis and necrosis. To the extent of our knowledge, this is the ®rst report of cell death morphology at the TEM level for cells exposed to a proteasome inhibitor. In this regard the results shown have impact with respect to the many recent reports of proteasome inhibitor-induced`apoptosis'. However, a more exhaustive evaluation of these ultrastructural . Note in the centrally located cell the extensive¯attening of the nuclear envelope, the margination and fragmentation of chromatin, two apoptotic features and the extensive disruption of the nuclear envelope, a necrotic feature. Also note that in this cell some mitochondria have lost matrix and the cytoplasm is distinctlỳ vesiculated' a classical feature of necrosis. (c) another representative ®eld of cells treated with ALLnL (100 mM). Note, the classically apoptotic cell with extensive apoptotic body formation at the bottom left hand side. Also note that the centrally located cell has a disjointed nuclear envelope, a necrotic feature. (d) Laser scanning confocal microscopy image of nuclear fragmentation in cells treated with ALLnL (50 mM) and stained with ETHD-1 features is required. We are currently evaluating the myriad of alterations in morphology occurring during prostate carcinoma of cell induction by ALLnL and various other proteasome inhibitors (lactacystin, MG-132, MG-116) using transmission electron microscopy and confocal imaging.
Discussion
There is emerging evidence that protease systems, in particular the ATP-dependent ubiquitin/26S proteasome pathway, play important roles in regulating the intracellular levels of cell cycle and stress response proteins (Weissman, 1997) . Proteins such as p27 Kip1 , various cyclins, p21 waf1 , c-mos, c-myc and p53 are degraded via the ATP-dependent ubiquitin/26S proteasome (Weissman, 1997) . In addition, stress signalinduced serine phosphorylation of IkBa, the cytoplasmic inhibitor of NF-kB nuclear import, prompts ubiquitinylation and its rapid degradation via the ATP-dependent ubiquitin/26S proteasome system (Palombella et al., 1994; Traenckner et al., 1994) . Furthermore, a temperature-sensitive defect in the ubiquitin-activating enzyme, E1, has been implicated as the basis for dysfunctional cell cycle progression in the ts85 mutant cell line (Finley et al., 1984) .
Naturally, the pivotal role of the ATP-dependent ubiquitin/proteasome pathway in properly regulating the levels of so many vital cell cycle related proteins, p53 and other candidate tumor suppressor proteins, has lead to proposals that the proteasome and by implication the numerous ubiquitin-conjugating enzymes represent fundamentally important cellular targets for the development of new anticancer and anti-in¯ammatory therapies (Rolfe et al., 1997) .
The study of proteasomal function has been facilitated by the identi®cation of low molecular weight cell membrane permeable inhibitor peptide aldehydes including ALLnL and ALLnM. Use of these agents at concentrations sucient to block proteasomal-mediated degradation of IkBa were sucient to induce cell death in prostate carcinoma cells. No observable cell death was induced in LNCaP or PC-3 cells treated with E64 at concentrations up to 100 mM. The inability of E64 to block IkBa degradation or induce cell death suggests that the eects of ALLnL and ALLnM are not mediated by their inhibition of calpain activity.
The failure of bcl-2 to protect against prostate carcinoma cell death induction resulting from inhibition of proteasomal activity is noteworthy in that bcl-2 expression has been shown to confer resistance to prostate cell death induction by divergent stresses including g-radiation, p53, ceramide, inhibitors of arachidonate metabolism, TNF-a, and androgen deprivation in an orthotopic animal model system (Beham et al., 1997; Herrmann et al., 1997a,b; Tu et al., 1995; Westin et al., 1997) . Several possibilities might account for the inability of bcl-2 to protect against proteasome inhibitors. The signaling capacity of bcl-2 might be directly inhibited by post-translational modi®cations following repression of proteasomal activity as has been reported during taxol-induced apoptosis in prostate carcinoma cells (Haldar et al., 1996; Blagosklonny et al., 1996) . However, these mechanisms are considered unlikely in that alterations in the amount or apparent molecular weight of bcl-2 protein by immunoblot analysis was not observed. These ®ndings also suggest that bcl-2 protein levels are not directly regulated by proteasomal activity. The signi®cance and mechanism of the observed decrease in bcl-x L protein is speculative. This ®nding may indicate that the sensitivity to cell death induction by the inhibition of proteasome function may be modulated by speci®c pro-survival members of the bcl-2 family. It remains a matter of interest whether proteasome inhibitors result in downregulation of other prosurvival members of the bcl-2 family, such as bag-1. It is equally likely that pro-apoptotic eectors such as bax, bad and bak might be stabilized by inhibition of proteasomal activity using proteasome inhibitors in prostate carcinoma cells, thereby shifting the balance of pro-death to pro-survival bcl-2 relatives in favor of cell death. In this regard, we consider that bax stabilization is highly likely considering a recent report that bax is ubiquitinated and a substrate of the proteasome (Chang et al., 1998) . We are currently investigating this notion.
However, our data stands in direct contrast to a recent report that lactacystin-induced apoptosis in Ewing sarcoma cells occurs via a bcl-2-sensitive pathway (Soldatenkov and Dritschillo, 1997). The reason(s) for the disagreement in our respective reports is unclear at present although numerous possibilities may be considered. For instance, one might consider the steady-state synthesis of proteasome substrates with pro-death eector activity that are cell type speci®c. A few notable examples of such 26S proteasome substrates include p21 waf1 , p27 Kip1 , p53 and bax. Another, credible possibility that should be evaluated is the extent to which synthetic peptide aldehydes, as compared to the Streptomyces metabolite Lactacystin, inhibit the catalytic threonine nucleophile activity of the 26S proteasome in whole cells. This is an appropriate consideration since ALLnL and ALLnM are competitive reversible inhibitors of proteasomal activity (Rock et al., 1994) while lactacystin is an irreversible inhibitor (Fenteany et al., 1995) . Moreover, in the crystal structure of the yeast 20S proteasome complex, the peptide aldehyde ALLnL can be found bound to all three active site threonines in the subunits b1, b2 and b5 (for a review see Ciechanover and Schwartz, 1998) . Lactacystin, conversely, is observed covalently bound exclusively to the b5 subunit. Thus, should subunits b1, b2 and b5 subunits have distinct substrate preferences, proteasome inhibitors of distinct classes (e.g. peptide aldehydes compared to lactacystin) with distinct cell permeability properties and b-subunit binding properties might have biochemically discrete properties in terms of which ubiquitinated substrates they block. From this, we can reasonably infer that dierent proteasome inhibitors will have distinct in¯uences with respect to cell death induction, including protection by bcl-2 and other pro-survival eector proteins.
The inability of bcl-2 to protect against ALLnLinduced cell death may be related to the observed upregulation of PAR-4 (prostate apoptosis response-4). PAR-4, contains a leucine zipper domain and a putative death domain that interacts with atypical isoforms of PKC and signals apoptosis (Diaz- , 1996) . PAR-4 is upregulated in rat ventral prostate following androgen-ablation coincident with the induction of apoptosis (Sells et al., 1994) . Ectopic expression of PAR-4 has been reported to be a sucient signal to induce apoptosis in NIH3T3 ®broblasts (Diaz-Meco et al., 1996) and can sensitize PC-3 prostate carcinoma cells to thapsigargin-induced apoptosis (Sells et al., 1997) . Whether the observed increase in PAR-4 protein in cells treated with ALLnL or ALLnM represents accumulation of ubuiquitinated PAR-4 due to inhibition of proteasomal activity, remains an important issue to clarify. Accumulation of c-jun protein following was also observed following ALLnL treatment and inhibition of proteasomal activity. It has previously been demonstrated that c-jun is tightly regulated by ubiquitindependent proteasomal cleavage (Trier et al., 1994) . It is noteworthy in this context that increased c-jun activity has been reported to be sucient to activate an apoptosis program in NIH3T3 ®broblasts (BossyWetzel et al., 1997) . Moreover, SAPK/JNK-mediated phosphorylation of c-jun appears to be requisite for apoptosis signaling by a variety of stimuli that activate the sphingomyelin cycle for ceramide synthesis (Verheij et al., 1996) . Together, these ®ndings suggest, but do not prove, that signaling through c-jun may be an important mediator of cell death resulting from proteasome inhibition.
The most direct data implicating the requisite function of the JNK stress pathway in proteasome inhibitor-induced cell death comes from Meriin et al., (1998) who reported that ectopic expression of either a catalytically defective mutant version of JNKK (SEK1) or a transcriptionally incompetent c-jun protein blocks the cleavage of a co-expressed fragment of the U1 ribonucleoprotein. In this report cell death induction was not reported on a per cell basis (i.e. transfected versus vector control cells). It is quite conceivable that enforced expression of the dominant negative JNKK or c-jun resulted in a potent block to U1 cleavage, yet failed to block cell death induction by a myriad of alternative cell death pathways. This issue must be addressed.
In consideration, we did not observe activation of p46 JNK1 or p54 JNK2 in LNCaP prostate carcinoma cells treated with ALLnL despite the induction of substantial cell stress. For this reason, it is unlikely that the JNK stress kinase pathway plays a principal role in cell death induction following ALLnL-induced inhibition of proteasomal activity in prostate carcinoma cells. Thus, it is not clear at present the extent to which c-jun stabilization plays a role in cell death induction by proteasome inhibitors in prostate carcinoma cells.
The ability of ALLnL to induce cell death in prostate carcinoma cells was not dependent on the presence of wild-type p53. Comparable rates of cell death were induced in LNCaP cells, which possess wild-type p53 (Issacs et al., 1991) , and PC-3 cells which possess a frame shift mutation at codon 138 and an inframe stop codon at position 169 of the p53 gene (Carroll et al., 1993; Issacs et al., 1991) . In this respect, our data are in apparent disagreement with the observations of others which demonstrate that ectopic expression of a dominant-negative p53 protein could suppress apoptosis signaling by the peptide aldeyhyde proteasome inhibitors, MG115 and PSI, in Rat-1 ®broblasts and PC12 pheochromocytoma cells (Lopes et al., 1996) . The p53-dependency of cell death observed in Rat-1 and PC12 cells treated with MG115 may be associated with context speci®c cellular eects not observed in the transformed and tumorigenic prostate carcinoma cells used in the present study. Likewise, the premise discussed above with respect to distinct biochemical readouts based on the inhibitory properties of structurally discrete proteasome inhibitors equally applies to this situation.
In conclusion, the crucial cell cycle-related activities of the substrate targets of the ATP-dependent ubiquitin/26S proteasome system make the proteasome system an excellent target for the development of new therapeutic agents designed to disrupt cell proliferation and cell survival. Inhibition of proteasome activity does not, however, invariably result in cell death induction and may, in some circumstances result in survival enhancement (Grimm et al., 1996; Sadoul et al., 1996) . These divergent results may be reconciled, should the inhibition of proteasomal activity have dierent eects on quiescent cells or dierentiated cells versus actively cycling tumor cells as reported (Drexler, 1997; Lopes et al., 1997; Tanimoto et al., 1997; Wu et al., 1996) . Such dierential eects may be the consequence of the accumulation of con¯icting signals for cell death and survival.
The induction of apoptosis resulting from inhibition of proteasomal activity is likely to be extremely complex. The accumulation of ubiquitinated cyclins, p53, p21, p27, cdc25, bax and other proteasome substrates may, for example have profound con¯ict signal eects on cells if external growth factor signals persist for cell proliferation. This example might hold particularly true should persistent inhibition of proteasomal activity result in the accumulation of particular cyclins, whose cell cycle coordinated proteolysis by the 26S proteasome is indispensable for cells to enter the next cell cycle phase. In this regard, we have observed that prostate carcinoma cells accumulate in G2/M phase of the cell cycle, under conditions which do not induce apoptosis (unpublished observations JL Herrmann) .
Notwithstanding the contrasting results obtained using dierent cell lines and structurally distinct proteasome inhibitors, the identi®cation of pharmacological agents that signal death in cells with elevated bcl-2 and independent of p53 may prove useful in the treatment of cancer patients given the frequency of these molecular alterations in human tumors and association of these alterations with therapy failure.
Materials and methods

Reagents
Ethidium homodimer-1 (ETHD) was obtained from Molecular Probes (Eugene, OR, USA) and solubilized in DMSO. RPMI medium and fetal bovine serum were purchased from Gibco/BRL (Gaithersburg, MD, USA). The anti-bcl-2 (D21), anti-bcl-X L (L-19), anti-p65 RelA (C-20), anti-IkBa/MAD-3 (FL), anti-STAT2 and anti-PAR-4 (R-334) rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). In addition, the anti-c-jun (KM-1) mouse monoclonal antibody was purchased from Santa Cruz Biotechnology, Inc. Anti-b-catenin was purchased from Transduction Labs (Lexington, KY, USA). Antiubiquitin antibody was obtained from Chemicon (Temecula, CA, USA). The horseradish peroxidase (HRP) conjugated secondary goat anti-rabbit IgG H+L antibody conjugated to horseradish peroxidase were purchased from Zymed (South San Francisco, CA, USA). The donkey anti-mouse IgG was obtained from Amersham (Arlington Heights, IL, USA). Recombinant human TNF-a was purchased from R&D Systems, Inc. (Minneapolis, MN, USA) and reconstituted in PBS containing 0.1% BSA. Reconstituted TNF-a was stored and handled in accordance with the manufacturer's directions. Nitrocellulose membranes were purchased from Micron Separations, Inc. (Westboro, MA, USA). The Enhanced Chemiluminescence (ECL) detection system was obtained from Amersham. Nacetyl-leucyl-leucyl-normethioninal (ALLnL), N-acetyl-leucyl-leucyl-normethioninal (ALLnM) and E64 were obtained from Calbiochem (San Diego, CA, USA) and prepared as fresh stock solutions in DMSO. Calcein-AM and ethidium homodimer-1 were obtained form Molecular Probes (Eugene, OR, USA) and prepared as stock solutions in DMSO. The synthetic lipids C 2 -ceramide, ETI (5,8,11-eicosatriynoic acid) and AACOCF 3 (arachidonyltrifluoromethyl ketone) were obtained from Biomol (Plymouth Meeting, PA, USA).
Cell lines and culture conditions
The prostatic carcinoma cell lines, LNCaP and LNCaPbcl-2, PC-3.neo4, PC-3.bcl-2-3 and PC-3-bcl-2-23, were cultured in RPMI medium supplemented with 10% fetal bovine serum without antibiotics. To obtain the stably transfected LNCaP and PC-3 bcl-2 cells, the parental cell lines were transfected (electroporation of 1.5610 7 cells/ 0.5 ml at 960 mF/300 V in PBS using 30 mg of DNA) with a linearized Splenic Focus Forming Virus-based expression vector containing a complete human bcl-2 cDNA (or empty vector as control). The isolation and characterization of the neo controls and bcl-2 congenic cell lines, LNCaP-bcl-2 and PC-bcl-2-23, has been described (Herrmann et al., 1997b) . Cells were maintained in a 5% humidi®ed CO 2 chamber and subcultured (1 : 10 split) once per week by typsinization (0.25% trypsin in calcium and magnesium-free phosphate buered saline).
Determination of cell viability and cell death
Cells were seeded at 1.0610 5 cells per well in 48 well plates. After 3 ± 5 days of culture in complete medium these cells were washed once with RPMI containing 0.5% FBS. Cells were then treated with the appropriate proteasome inhibitor (25 ± 100 mM ALLnL or ALLnM) or control (E64) protease inhibitor prepared fresh in DMSO and diluted into RPMI containing 0.5% FBS. Cells were also similarly treated with 10 mM C 2 -ceramide, 10 mM AACOCF 3 or 10 mM ETI. For experiments involving cotreatment of cells with TNF-a and proteasome inhibitors, the cells were preloaded with proteasome inhibitors for 45 min prior to TNF-a stimulation. Each treatment group was performed in triplicate and in RPMI containing 0.5% FBS. At various times following application of the proteasome inhibitors the cells were washed with complete medium and then were incubated for 20 min at 378C with complete medium containing 1 mg/ml the acetoxymethyl ester derivative of calcein (CAM) with or without 1 mg/ml ethidium homodimer ETHD-1. Cells were washed twice with serum free medium and changed to complete medium. Measurement of intracellular calcein was performed using a Cyto¯uor model 2350 (Millipore) uorometric microplate reader using a 485 nm excitation ®lter and a 530 emission ®lter set. Relative cell viability was made by comparison of experimental wells to control wells treated with DMSO carrier. Additionally, cells were photographed using epi¯uorescence illumination using an Olympus IX70 microscope and a Omega Vivid XF52 dual band ®lter set.
To assess apoptosis cells were plated on laminin-coated (10 mg/ml) glass coverslips and treated 4 days later as described above with various proteasome inhibitors, loaded with ETHD-1 as described, washed twice with PBS, ®xed with 95% cold methanol for 10 min, washed twice with PBS, and mounted on glass slides and ®nally visualized by laser scanning confocal microscopy visualized using a Zeiss Model 410 confocal microscrope (568 excitation and 590 emission ®lters).
Immunoblot analysis
Subcon¯uent cells, cultured without G418, were washed once with PBS and lysed with 26SDS-PAGE sample loading buer. Cell lysis volumes were adjusted to re¯ect cell counts taken from other plates. DNA was sheared by 20 passages through a 25 g needle. Samples were boiled for 5 min and centrifuged at 10 000 g for 5 min to remove any particulate material. Proteins were resolved on 12.5% polyacrylamide gels and electroblotted to a nitrocellulose membrane. Membranes were blocked in PBS containing 0.1% Tween-20 and 4% nonfat dry milk for 1 h at room temperature. Blocked membranes were probed with the appropriate primary antibody (all primaries were used at dilutions of 1 : 5000) in PBS containing 0.1% Tween-20 and 4% nonfat dry milk, for 1 h at room temperature, washed six times for 10 min per wash and probed with secondary goat anti-rabbit IgG (1 : 50 000) or, when appropriate, secondary donkey anti-mouse IgG (1 : 5000) coupled to horseradish peroxidase. Detection of bound secondary antibodies was performed using Enhanced Chemiluminescence (ECL) as per the manufacturer's directions.
Transmission electron microscopy
Cells stimulated with ALLnL (100 mM, in 0.5% FBS-RPMI) for 24 h were pelleted in 15 ml centrifuge tubes, gently washed with PBS and recovered. The pellet was ®xed in ice cold TEM ®xation buer (2% EM-grade glutaraldehyde in 0.2 M sodium cacodylate buer). The ®xed pellet was embedded in epon (EM bed-812, epon 812 substitute, Electron Microscopy Sciences, Fort Washington, PA, USA). Sections were cut using a Reichert-Jung untramicrotone and viewed using a Joel-1200EXII transmission electron microscope (JOEL Ltd, Tokyo, Japan). Original TEM photographs were scanned in Photoshop v4.0. Contrast was manipulated to accurately re¯ect the original images.
